• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

疟原虫 vivax 疟疾的预防和治疗。

The prevention and treatment of Plasmodium vivax malaria.

机构信息

Shoklo Malaria Research Unit-Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Headington, Oxford, United Kingdom.

出版信息

PLoS Med. 2021 Apr 23;18(4):e1003561. doi: 10.1371/journal.pmed.1003561. eCollection 2021 Apr.

DOI:10.1371/journal.pmed.1003561
PMID:33891587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8064578/
Abstract

Cindy S Chu and co-authors review options for diagnosis, safe and radical cure, and relapse prevention of Plasmodium Vivax.

摘要

辛迪·S·楚（Cindy S Chu）及其合著者回顾了诊断、安全根治和预防间日疟原虫（Plasmodium Vivax）复发的选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6659/8064578/7f593dd96eb2/pmed.1003561.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6659/8064578/a00fceb6d09e/pmed.1003561.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6659/8064578/bd1823878de1/pmed.1003561.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6659/8064578/7f593dd96eb2/pmed.1003561.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6659/8064578/a00fceb6d09e/pmed.1003561.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6659/8064578/bd1823878de1/pmed.1003561.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6659/8064578/7f593dd96eb2/pmed.1003561.g003.jpg

相似文献

1
The prevention and treatment of Plasmodium vivax malaria.疟原虫 vivax 疟疾的预防和治疗。
PLoS Med. 2021 Apr 23;18(4):e1003561. doi: 10.1371/journal.pmed.1003561. eCollection 2021 Apr.
2
[Research progress on Plasmodium vivax chloroquine resistance].间日疟原虫氯喹耐药性的研究进展
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2014 Jun;26(3):326-31.
3
Advancing Research Models and Technologies to Overcome Biological Barriers to Plasmodium vivax Control.推进研究模型和技术以克服控制间日疟原虫的生物学障碍。
Trends Parasitol. 2018 Feb;34(2):114-126. doi: 10.1016/j.pt.2017.10.009. Epub 2017 Nov 16.
4
Taking on Plasmodium vivax malaria: A timely and important challenge.应对间日疟原虫疟疾：一个及时且重要的挑战。
PLoS Med. 2021 Apr 23;18(4):e1003593. doi: 10.1371/journal.pmed.1003593. eCollection 2021 Apr.
5
Primaquine treatment and relapse in Plasmodium vivax malaria.间日疟原虫疟疾的伯氨喹治疗与复发
Pathog Glob Health. 2016;110(1):1-8. doi: 10.1080/20477724.2015.1133033. Epub 2016 Feb 18.
6
How radical is radical cure? Site-specific biases in clinical trials underestimate the effect of radical cure on Plasmodium vivax hypnozoites.根治性治疗的激进程度如何？临床试验中的特定部位偏倚低估了根治性治疗对间日疟原虫休眠子的作用。
Malar J. 2021 Dec 20;20(1):479. doi: 10.1186/s12936-021-04017-1.
7
Progress towards safer and more effective radical cure of Plasmodium vivax.在实现间日疟原虫更安全、更有效的根治方面取得的进展。
Lancet Infect Dis. 2024 Jun;24(6):565-567. doi: 10.1016/S1473-3099(24)00139-7. Epub 2024 Mar 4.
8
The importance of being vivax.间日疟原虫存在的重要性。
J Trop Pediatr. 2014 Oct;60(5):335-7. doi: 10.1093/tropej/fmu053.
9
Blood-stage dynamics and clinical implications of mixed Plasmodium vivax-Plasmodium falciparum infections.间日疟原虫与恶性疟原虫混合感染的血液期动态变化及临床意义
Am J Trop Med Hyg. 1999 Sep;61(3):367-74. doi: 10.4269/ajtmh.1999.61.367.
10
Epidemiology and Control of Plasmodium vivax in Afghanistan.阿富汗间日疟原虫的流行病学与防控
Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):72-77. doi: 10.4269/ajtmh.16-0172. Epub 2016 Oct 5.

引用本文的文献

1
A common DNA deletion altering the 3'UTR of is associated with reduced mefloquine susceptibility in parasites from Cambodian patients.一种常见的DNA缺失改变了（此处原文缺失具体基因名称）的3'非翻译区，这与柬埔寨患者寄生虫中对甲氟喹的敏感性降低有关。
Res Sq. 2025 Sep 1:rs.3.rs-6889263. doi: 10.21203/rs.3.rs-6889263/v1.
2
Piloting the options assessment toolkit with national malaria programme leaders from the Asia-Pacific countries: a meeting report.与亚太国家国家疟疾规划负责人共同试用选项评估工具包：会议报告
Malar J. 2025 Jun 12;24(1):187. doi: 10.1186/s12936-025-05432-4.
3
Assessment of Plasmodium vivax transmission and asymptomatic carriage risk among artisanal gold miners in western French Guiana, 2014-2020.

本文引用的文献

1
Anti-malarial drug effects on parasite dynamics in vivax malaria.抗疟药物对 vivax 疟疾寄生虫动力学的影响。
Malar J. 2021 Mar 21;20(1):161. doi: 10.1186/s12936-021-03700-7.
2
Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against malaria.地中海型葡萄糖-6-磷酸脱氢酶缺乏症对疟疾的保护作用。
Elife. 2021 Feb 5;10:e62448. doi: 10.7554/eLife.62448.
3
The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia.印度尼西亚巴布亚地区使用和不使用伯氨喹治疗间日疟原虫疟疾后不良临床结局的风险。
2014 - 2020年法属圭亚那西部手工淘金者间间日疟原虫传播及无症状携带风险评估
Infect Dis Poverty. 2025 May 26;14(1):40. doi: 10.1186/s40249-025-01306-8.
4
Health Education Campaign to Improve Malaria Knowledge, Prevention, and Treatment Behaviors in Rural East Nusa Tenggara Province, Indonesia: Protocol for a Cluster-Assigned Quasi-Experimental Study.印度尼西亚东努沙登加拉省农村地区提高疟疾知识、预防和治疗行为的健康教育运动：一项整群分配的准实验研究方案
JMIR Res Protoc. 2025 May 1;14:e66982. doi: 10.2196/66982.
5
Parasitaemia and fever in uncomplicated Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis.间日疟原虫单纯性疟疾的寄生虫血症与发热：一项系统评价和个体患者数据荟萃分析
PLoS Negl Trop Dis. 2025 Mar 28;19(3):e0012951. doi: 10.1371/journal.pntd.0012951. eCollection 2025 Mar.
6
Assessing the Feasibility of Using a Multiplex Serological Assay to Conduct Serosurveillance for Malaria Exposure in Deployed Military Personnel.评估使用多重血清学检测对部署的军事人员进行疟疾暴露血清学监测的可行性。
Trop Med Infect Dis. 2025 Jan 2;10(1):13. doi: 10.3390/tropicalmed10010013.
7
Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages.针对间日疟原虫前体红细胞期和血液期的强效AMA1特异性人单克隆抗体。
Nat Commun. 2024 Dec 4;15(1):10556. doi: 10.1038/s41467-024-53848-4.
8
Diagnostic accuracy of the point-of-care standard G6PD test™ (SD Biosensor) for glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis.即时护理点 G6PD 检测试验（SD 生物传感器）诊断葡萄糖-6-磷酸脱氢酶缺乏症的准确性：系统评价和荟萃分析。
Malar J. 2024 Nov 2;23(1):327. doi: 10.1186/s12936-024-05144-1.
9
Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis.儿童小于 15 岁的无并发症间日疟原虫疟疾采用磷酸咯萘啶治疗：系统评价和个体患者数据分析荟萃分析。
Lancet Child Adolesc Health. 2024 Nov;8(11):798-808. doi: 10.1016/S2352-4642(24)00210-4. Epub 2024 Sep 24.
10
Glucose-6-phosphate Dehydrogenase Variants: Analysing in Indian Plasmodium vivax Patients.葡萄糖-6-磷酸脱氢酶变异体：对印度间日疟原虫患者的分析。
Acta Parasitol. 2024 Sep;69(3):1522-1529. doi: 10.1007/s11686-024-00883-2. Epub 2024 Aug 20.
PLoS Negl Trop Dis. 2020 Nov 11;14(11):e0008838. doi: 10.1371/journal.pntd.0008838. eCollection 2020 Nov.
4
Re-introduction of vivax malaria in a temperate area (Moscow region, Russia): a geographic investigation.在温带地区（俄罗斯莫斯科地区）重新引入间日疟原虫：一项地理调查。
Malar J. 2020 Mar 18;19(1):116. doi: 10.1186/s12936-020-03187-8.
5
Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review.磷酸萘酚喹预防间日疟复发的神经和精神安全性：综述。
Malar J. 2020 Mar 14;19(1):111. doi: 10.1186/s12936-020-03184-x.
6
Resolving the cause of recurrent Plasmodium vivax malaria probabilistically.概率解决间日疟原虫疟疾复发的原因。
Nat Commun. 2019 Dec 6;10(1):5595. doi: 10.1038/s41467-019-13412-x.
7
A review of the WHO malaria rapid diagnostic test product testing programme (2008-2018): performance, procurement and policy.世卫组织疟疾快速诊断检测产品测试规划（2008-2018）回顾：性能、采购和政策。
Malar J. 2019 Dec 2;18(1):387. doi: 10.1186/s12936-019-3028-z.
8
Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019.2019 年美国使用他非诺喹预防和抗复发性疟疾的指南。
MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1062-1068. doi: 10.15585/mmwr.mm6846a4.
9
Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute Plasmodium vivax malaria in northeast Myanmar: A prospective open-label efficacy trial.缅甸东北部直接观察下氯喹-伯氨喹治疗无并发症急性间日疟原虫疟疾的疗效：一项前瞻性开放标签疗效试验。
Travel Med Infect Dis. 2020 Jul-Aug;36:101499. doi: 10.1016/j.tmaid.2019.101499. Epub 2019 Oct 8.
10
The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.氯喹治疗后有无伯氨喹治疗对间日疟原虫疟疾的血液学后果：全球抗疟药物耐药网络系统评价和个体患者数据荟萃分析。
BMC Med. 2019 Aug 1;17(1):151. doi: 10.1186/s12916-019-1386-6.